Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease

Reviews on Environmental Health

Volumn 17, Issue 1, 2002, Pages 51-64

  Le Couteur, David G ^a   Muller, Michael ^a   Yang, Maria C ^a   Mellick, George D ^a   McLean, Allan J ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Aging; Parkinson's disease; Pesticides; Xenobiotic metabolism

Indexed keywords

ALPHA SYNUCLEIN; HEAVY METAL; NEUROTOXIN; PESTICIDE;

AGE; AGING; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LEWY BODY; MESENCEPHALON; NEUROTOXICITY; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SUBSTANTIA NIGRA; XENOBIOTIC METABOLISM;

AGING; ENVIRONMENTAL EXPOSURE; HUMANS; NEUROTOXINS; PARKINSON DISEASE; XENOBIOTICS;

EID: 0036375516     PISSN: 00487554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. The epidemiology of Parkinson's disease in an Australian population
2. Worldwide occurrence of Parkinson's disease: An updated review
3. Risk tables for parkinsonism and Parkinson's disease
4. Pathogenesis of idiopathic parkinsonism
5. Pathogenesis and animal studies of Parkinson's disease
6. A brief history of parkinsonism
7. Molecular genetics of Parkinson's disease
8. Genetics of Parkinsonism: A review
9. Pesticides and Parkinson's disease
10. Epidemiology versus genetics in Parkinson's disease: Progress in resolving an age-old debate
11. Current theories on the cause of Parkinson's disease
12. Genetic epidemiology of Parkinson's disease
13. Parkinson disease in twins: An etiologic study
14. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins
15. Familial aggregation of Parkinson's disease in Iceland
16. Genetics of Parkinson's disease
17. Genetics of Parkinson's disease
18. Mutation in the α-synuclein gene identified in families with Parkinson's disease
19. The alpha-synuclein gene and Parkinson disease in a Chinese population
20. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
21. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
22. The parkin gene and its phenotype
23. Lewy bodies and parkinsonism in families with parkin mutations
24. The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls
25. Failure of the ubiquitin-proteasome system in Parkinson's disease
26. The ubiquitin pathway in Parkinson's disease
27. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease
28. The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease
29. Chronic parkinsonism in humans due to a product of meperidine analog synthesis
30. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
31. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetra-hydropyrine (MPTP) in the squirrel monkey
32. Interactions between MPTP-induced and age-related neuronal death in a murine model of Parkinson's disease
33. Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs
34. Development of a model for Parkinson's disease in sheep using unilateral intracarotid injection of MPTP via slow continuous infusion
35. Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease
36. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations
37. The etiology of Parkinson's disease with emphasis on the MPTP story
38. Influence of environmental factors on the onset of Parkinson's disease
39. The role of environmental toxins in the etiology of Parkinson's disease
40. Hepatic disposition of neurotoxins and pesticides
41. Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the liver and systemic bioavailability
42. Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6)-tetra-hydropyridine in mice
43. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
44. Neurological consequence of industrial exposure to 1-methyl-4-pheny1-1,2,3,6-tetrahydropyridine
45. Parkinson's disease: A case-control study of occupational and environmental risk factors
46. Environmental risk factors and Parkinson's disease: A case-control study in Taiwan
47. A meta-analysis of Parkinson's disease and exposure to pesticides
48. A case-control study of Parkinson's disease in urban population of southern Israel
49. Genetic and environmental risk factors for Parkinson's disease in a Chinese population
50. Parkinson's disease mortality and pesticide exposure in Calfornia 1984-1994
51. Agricultural work and the risk of Parkinson's disease in Denmark, 1981-1993
52. Acute and reversible parkinsonism due to organo-phosphate pesticide intoxication: Five cases
53. Environmental, medical, and family history risk factors for Parkinson's disease: A New England-based case control study
54. Risk factors of Parkinson's disease in Indian patients
55. Parkinson's disease and brain levels of organochlorine pesticides
56. Organochlorine insecticides in substantia nigra in Parkinson's disease
57. Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease
58. Environmental risk factors and Parkinson's disease: A metaanalysis
59. Occupational metal exposures and the risk of Parkinson's disease
60. Parkinsonism induced by solvent abuse
61. Welding-related parkinsonism: Clinical features, treatment, and pathophysiology
62. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein
63. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death
64. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: A possible factor in Parkinson's disease
65. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein
66. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure
67. Induction of alpha-synuclein aggregation by intracellular nitrative insult
68. Crosslinking of alpha-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation?
69. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein
70. Pesticide-induced oxidative stress: Perspectives and trends
71. Dieldrin-induced oxidative stress and neuro-chemical changes contribute to apoptopic cell death in dopaminergic cells
72. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons
73. Preservation of midbrain catecholaminergic neurons in very old human subjects
74. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease
75. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease
76. Nigrostriatal monoamine oxidase A and B in aging squirrel monkeys and C57BL/6 mice
77. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys
78. Age-dependent effects of the 2′-methyl analog of 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine: Prevention by inhibitors of monoamine oxidase
79. Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice
80. Ultrastructure of eosinophilic inclusion bodies in the amygdala-parahippocampal region of aged squirrel monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin
81. MPTP-induced oxidative stress and neurotoxicity are age-dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels
82. Comparison of brain dopamine depletion induced by low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in young and aged rats
83. Effects of aging on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxic effects on striatum and brainstem in the rat
84. Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets
85. MPTP aging. Studies in the C57BL/6 mouse
86. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: A critical reassessment
87. Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice
88. Age-related effects of MPTP on norepinephrine concentrations of various areas of rat brains
89. Comparative studies of the neurotoxicity of MPTP in rats of different ages
90. MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF)
91. Long-term effect of MPTP in the mouse brain in relation to aging: Neurochemical and immunocytochemical analysis
92. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the rat: Characterization and age-dependent effects
93. The sensitivity of nigrostriatal dopamine neurons to MPP+ does not increase with age
94. The bio11-transformation of MPTP and disposition of MPP+: The effects of aging
95. Aging and 1-methyl-4-pheny-1-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra
96. Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) on striatal dopamine content in young and mature mice
97. Effects of N-methylmercaptoimidazole on the disposition of MPTP and its metabolites in mice
98. Further investigation of allopurinol effects on MPTP-induced oxidative stress in the striatum and brain stem of the rat
99. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP
100. Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
101. Differential age-related changes in MAO-A and MAO-B in mouse brain and peripheral organs
102. Monoamine oxidase, brain aging and degenerative diseases
103. Age-related changes of MAO in B1/C57 mouse tissues: A quantitative radioautographic study
104. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species
105. Aging is associated with altered hepatic disposition of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pesticides
106. Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine in mice
107. The aging liver: Drug clearance and an oxygen diffusion barrier hypothesis
108. Pseudo-capillarization and associated energy limitation in the aged rat liver
109. Hepatic pseudocapillarisation and atherosclerosis in aging
110. 1-Methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, IA2 and 3A4-implications for Parkinson's disease
111. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine
112. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: A case-control study and meta-analysis
113. Neurogenetic correlates of Parkinson's disease: Apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism
114. P450 enzymes and Parkinson's disease
115. Genetoxin interaction as a putative risk factor for Parkinson's disease with dementia
116. Parkinson's disease, pesticides and glutathione transferase polymorphisms
117. Zeta class glutathione transferase polymorphisms and Parkinson's disease
118. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population
119. An association between idiopathic Parkinson's disease and polymorphisms of phase 11 detoxification enzymes: Glutathione S-transferase M1 and quinone oxidoreductase 1 and 2
120. An allelic association study of monoamine oxidase B in Parkinson's disease
121. Association of a monoamine oxidase B allele with Parkinson's disease
122. Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease
123. The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population
124. A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease
125. Parkinson's disease, MAOB, and smoking
126. Parkinson's disease: Nature meets nuture